Liquidia Corporation - Common Stock (LQDA)

United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company cemented its status as a high-performance healthcare powerhouse by reporting a significant Q4 2025 earnings beat and officially surpassing the $3 billion annual revenue milestone for [...]

As of February 26, 2026, United Therapeutics Corporation (NASDAQ: UTHR) stands at a pivotal crossroads in the biotechnology sector. Long recognized as a dominant force in the treatment of pulmonary arterial hypertension (PAH), the company has recently captured Wall Street’s attention with a series of high-stakes maneuvers. Following a stellar Q4 2025 earnings report released [...]

The company is clearly benefiting from the solid momentum of its newest drug on the market.

Liquidia Corp (LQDA) exemplifies a high-growth momentum stock in a strong technical uptrend, combining surging revenue with a top-rated chart pattern.

One fund just walked away from a rising offshore driller—here’s what long-term investors should make of the move.

A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional attention.

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Liquidia (LQDA) stock shows a powerful technical uptrend and explosive 1,121% revenue growth, aligning with the high-momentum Minervini strategy.

Liquidia's Q3 2025 results crushed expectations with $54.3M revenue, driven by the successful launch of YUTREPIA. The stock surged as the company moves toward profitability.

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance at week 16.